Kymera Therapeutics, Inc. (KYMR) stock
KYMRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/30227% above fair value
$121.13−0.39 (-0.32%)
Close on Nov 18, 2026Market cap $10.34BP/E –Yield –
Kymera Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Kymera Therapeutics's enterprise value was $10.47B on Nov 11, 2026, against $4.36B a year earlier. Over the last 5 years it ranged from $278.83M to $10.47B, with a median of $1.74B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $10.47B | +106.3% |
| 2025 | Dec 31, 2025 | $5.08B | +147.0% |
| 2024 | Dec 31, 2024 | $2.05B | +95.0% |
| 2023 | Dec 29, 2023 | $1.05B | +19.1% |
| 2022 | Dec 30, 2022 | $884.69M | -67.4% |
| 2021 | Dec 31, 2021 | $2.72B | +10.4% |
| 2020 | Dec 31, 2020 | $2.46B | – |
See a number that looks wrong?